These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 22493727)
21. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Zeng Y; Li C; Guan M; Zheng Z; Li J; Xu W; Wang L; He F; Xue Y Cardiovasc Diabetol; 2014 Feb; 13():32. PubMed ID: 24490809 [TBL] [Abstract][Full Text] [Related]
22. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403 [TBL] [Abstract][Full Text] [Related]
23. Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats. Min KM; Park SW; Cho KY; Song MS; Kim DK; Park GS; Lee MK Metabolism; 2002 Aug; 51(8):998-1002. PubMed ID: 12145772 [TBL] [Abstract][Full Text] [Related]
24. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Kim SY; Kwon YW; Jung IL; Sung JH; Park SG Cardiovasc Res; 2011 Nov; 92(2):307-16. PubMed ID: 21840882 [TBL] [Abstract][Full Text] [Related]
25. Human urine kininogenase attenuates balloon-induced intimal hyperplasia in rabbit carotid artery through transforming growth factor β1/Smad2/3 signaling pathway. Lan W; Yang F; Li Z; Liu L; Sang H; Jiang Y; Xiong Y; Zhang R J Vasc Surg; 2016 Oct; 64(4):1074-83. PubMed ID: 26054589 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor. Chen J; Zhang J; Xu L; Xu C; Chen S; Yang J; Jiang H Atherosclerosis; 2012 Oct; 224(2):332-9. PubMed ID: 22857898 [TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of n-butylidenephthalide on neointimal hyperplasia in balloon injured rat carotid artery. Liu WS; Lin PC; Chang LF; Harn HJ; Shiuan D; Chiou TW; Jeng JR Phytother Res; 2011 Oct; 25(10):1494-502. PubMed ID: 21365711 [TBL] [Abstract][Full Text] [Related]
28. Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Price JD; Linder G; Li WP; Zimmermann B; Rother KI; Malek R; Alattar M; Tarbell KV Clin Exp Immunol; 2013 Oct; 174(1):120-8. PubMed ID: 23711188 [TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Jackson EK; Kochanek SJ; Gillespie DG Hypertension; 2012 Sep; 60(3):757-64. PubMed ID: 22802229 [TBL] [Abstract][Full Text] [Related]
30. Nitric oxide differentially affects proteasome activator 28 after arterial injury in type 1 and type 2 diabetic rats. Tsihlis ND; Rodriguez MP; Jiang Q; Schwartz A; Flynn ME; Vercammen JM; Kibbe MR J Surg Res; 2016 May; 202(2):413-21. PubMed ID: 27229117 [TBL] [Abstract][Full Text] [Related]
31. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Ruef J; Meshel AS; Hu Z; Horaist C; Ballinger CA; Thompson LJ; Subbarao VD; Dumont JA; Patterson C Circulation; 1999 Aug; 100(6):659-65. PubMed ID: 10441105 [TBL] [Abstract][Full Text] [Related]
32. Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin. Lu YL; Zhou DQ; Zhai HL; Wu H; Guo ZK Chin Med J (Engl); 2012 May; 125(10):1690-4. PubMed ID: 22800885 [TBL] [Abstract][Full Text] [Related]
33. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Mega C; de Lemos ET; Vala H; Fernandes R; Oliveira J; Mascarenhas-Melo F; Teixeira F; Reis F Exp Diabetes Res; 2011; 2011():162092. PubMed ID: 22203828 [TBL] [Abstract][Full Text] [Related]
34. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. Kubota Y; Miyamoto M; Takagi G; Ikeda T; Kirinoki-Ichikawa S; Tanaka K; Mizuno K J Korean Med Sci; 2012 Nov; 27(11):1364-70. PubMed ID: 23166419 [TBL] [Abstract][Full Text] [Related]
36. EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. Lim S; Yoon JW; Kang SM; Choi SH; Cho BJ; Kim M; Park HS; Cho HJ; Shin H; Kim YB; Kim HS; Jang HC; Park KS PLoS One; 2011; 6(6):e20301. PubMed ID: 21655098 [TBL] [Abstract][Full Text] [Related]
37. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784 [TBL] [Abstract][Full Text] [Related]
38. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice. Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961 [TBL] [Abstract][Full Text] [Related]
39. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Ohlsson L; Alsalim W; Carr RD; Tura A; Pacini G; Mari A; Ahrén B Diabetes Obes Metab; 2013 Jun; 15(6):531-7. PubMed ID: 23331498 [TBL] [Abstract][Full Text] [Related]
40. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells. Brenner C; Kränkel N; Kühlenthal S; Israel L; Remm F; Fischer C; Herbach N; Speer T; Grabmaier U; Laskowski A; Gross L; Theiss H; Wanke R; Landmesser U; Franz WM Int J Cardiol; 2014 Nov; 177(1):266-75. PubMed ID: 25499391 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]